Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192215 · ClinicalTrials.gov registry record · Phase 3
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
A Phase 3 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,015
- Enrollment target
NCT03192215 is a Phase 3 study that was terminated before completion, run by Columbia University. The registered enrollment target is 1,015 participants.
The verdict
NCT03192215, a Phase 3 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,015 participants
- Enrollment target
Study Summary
Objectives * Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. * Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
Interventions
- DRUG Aspirin
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,015 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2023-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03192215
The ClinicalTrials.gov registry entry for NCT03192215 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,015 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT03192215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03192215 about?
NCT03192215 is a clinical study titled "AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke". Objectives * Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy. * Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the se...
What is the current status of trial NCT03192215?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,015 participants. The study started on 2018-01-19. Estimated completion is 2023-04-17.
What interventions are being tested in trial NCT03192215?
The interventions under investigation include: Aspirin (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT03192215?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.